Key result
Branched-chain amino acids are linked to higher cardiometabolic disease, kidney disease, and stroke risk.
Answers are grounded in this paper and cite their sources.
PURPOSE OF REVIEW: There is burgeoning evidence that branch chain amino acids (BCAAs) are biomarkers of metabolic, cardiovascular, renal and cerebrovascular disease. The purpose of this review is to summarize the current evidence in this area. RECENT FINDINGS: Recent evidence demonstrates that BCAAs are associated with insulin resistance, type 2 diabetes, risk of cardiovascular disease, stage I and II chronic kidney disease and ischemic stroke. Further, circulating levels of BCAAs have the potential to predict populations at risk for cardiometabolic disease, type 2 diabetes and mortality from ischemic heart disease. Importantly, the relationship of BCAAs to insulin resistance is affected by the intake of fat in the diet as well as age. SUMMARY: Current evidence supports the potential use of BCAAs as biomarkers of disease. However, questions regarding the mechanisms underlying the relationship of BCAAs to disease process and severity need to be answered prior to the use of BCAAs as a biomarker in clinical practice.
No takes yet. Share an insight, caveat, or question.
Batch et al. (2013) conducted a review in Cardiometabolic, renal, and cerebrovascular diseases. Branch chain amino acids (BCAAs) was evaluated. Branch chain amino acids are associated with insulin resistance, type 2 diabetes, cardiovascular disease risk, chronic kidney disease, and ischemic stroke, supporting their potential use as biomarkers.
Synapse has enriched 10 related papers. Consider them for comparative context: